Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93125ArticlesСтатьиResearch ArticleMoksifloksatsin: mesto v ryadu ftorkhinolonov i klinicheskoe znachenieМоксифлоксацин: место в ряду фторхинолонов и клиническое значениеSidorenkoS. VСидоренкоС. ВНаучно-исследовательский институт детских инфекций, Санкт-ПетербургРГМУ, Москва15042010124VOL 12, NO4 (2010)ТОМ 12, №4 (2010)293428122021Copyright ©; 2010, Consilium MedicumCopyright ©; 2010, ООО "Консилиум Медикум"2010Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93125

Антибактериальные препараты группы хинолонов известны в медицинской практике достаточно давно. Первым представителем этой группы, внедренным в медицинскую практику в качестве антибактериального препарата в 1962 г., была налидиксовая кислота. Спектр действия налидиксовой кислоты ограничивается некоторыми грамотрицательными микроорганизмами, а область клинического применения – инфекциями мочевыводящих путей. Толчком к интенсивному развитию всей группы послужило введение атома фтора в 6-е положение молекулы хинолонов. Первым клинически доступным фторированным препаратом явился норфлоксацин. Некоторые этапы развития фторхинолонов представляются весьма драматичными. Ряд препаратов, прошедших клинические испытания и допущенных к медицинскому применению, был отозван из-за обнаружения серьезных побочных эффектов (тосуфлоксацин, тровафлоксацин, грепафлоксацин). Разработка некоторых препаратов была прекращена на различных стадиях доклинического и клинического изучения.

Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000; 46 (Suppl. T1): 17–24.Andriole V.T. The quinolones: past, present, and future. Clin Infect Dis 2005; 41 (Suppl. 2): S113–9.Van Bambeke F, Michot J.M, Van Eldere J, Tulkens P.M. Quinolones in 2005: an update. Clin Microbiol Infect 2005; 11 (4): 256–80.Naber K.G, Adam D, Chemotherapy aaegot PESf: [Classification of fluoroquinolones.]. Chemother J 1998; 7: 66–8.Torres A, Garau J, Arvis P et al. Moxifloxacin monotherapy is effective in hospitalized patients with community - acquired pneumonia: the MOTIV study – a randomized clinical trial. Clin Infect Dis 2008; 46 (10): 1499–509.Welte T, Petermann W, Schurmann D et al. Treatment with sequential intravenous or oral moxifloxacin was associated with faster clinical improvement than was standard therapy for hospitalized patients with community - acquired pneumonia who received initial parenteral therapy. Clin Infect Dis 2005; 41 (12): 1697–705.Portier H, Brambilla C, Garre M et al. Moxifloxacin monotherapy compared to amoxicillin - clavulanate plus roxithromycin for nonsevere community - acquired pneumonia in adults with risk factors. Eur J Clin Microbiol Infect Dis 2005; 24 (6): 367–76.Anzueto A, Niederman M.S, Pearle J et al. Community - Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42 (1): 73–81.Lim W.S, Baudouin S.V, George R.C et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl. 3): iii1–55.Mandell L.A, Wunderink R.G, Anzueto A et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community - acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27–72.Sachs A.P, Koeter G.H, Groenier K.H et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50 (7): 758–63.Bent S, Saint S, Vittinghoff E, Grady D. Antibiotics in acute bronchitis: a meta - analysis. Am J Med 1999; 107 (1): 62–7.Saint S, Bent S, Vittinghoff E, Grady D. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta - analysis. JAMA 1995; 273 (12): 957–60.Wilson R, Allegra L, Huchon G et al. Short - term and long - term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125 (3): 953–64.Miravitlles M, Llor C, Molina J et al. Antibiotic treatment of exacerbations of COPD in general practice: long - term impact on health - related quality of life. Int J Chron Obstruct Pulmon Dis 2010; 5: 11–9.Meguro M, Barley E.A, Spencer S, Jones P.W. Development and Validation of an Improved, COPD - Specific Version of the St. George Respiratory Questionnaire. Chest 2007; 132 (2): 456–63.Sethi S, Jones P.W, Theron M.S et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11: 10.Burke T, Villanueva C, Mariano H.Jr et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Sinusitis Infection Study Group. Clin Ther 1999; 21 (10): 1664–77.Siegert R, Gehanno P, Nikolaidis P et al. A comparison of the safety and efficacy of moxifloxacin (BAY 12–8039) and cefuroxime axetil in the treatment of acute bacterial sinusitis in adults. The Sinusitis Study Group. Respir Med 2000; 94 (4): 337–44.Rakkar S, Roberts K, Towe B.F et al. Moxifloxacin versus amoxicillin clavulanate in the treatment of acute maxillary sinusitis: a primary care experience. Int J Clin Pract 2001; 55 (5): 309–15.Solomkin J, Zhao Y.P, Ma E.L et al. Moxifloxacin is non - inferior to combination therapy with ceftriaxone plus metronidazole in patients with community - origin complicated intra - abdominal infections. Int J Antimicrob Agents 2009; 34 (5): 439–45.Heystek M, Ross J.D. A randomized double - blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease. Int J STD AIDS 2009; 20 (10): 690–5.Sacco F, Spezzaferro M, Amitrano M et al. Efficacy of four different moxifloxacin - based triple therapies for first - line H. pylori treatment. Dig Liver Dis 2010; 42 (2): 110–4.